HOME >> MEDICINE >> NEWS
Clinical study results using Aldagen's product to isolate cord blood stem cells presented at ASH

Durham, NC -- December 11, 2006 Aldagen, Inc. today announced the presentation of data from a clinical trial using its ALDESORT product to isolate stem cells from cord blood. The trial is being conducted by Joanne Kurtzberg, MD, the Duke University physician who pioneered the use of umbilical cord blood as a treatment for fatal childhood cancers and genetic diseases in 1993. Dr. Kurtzberg presented positive interim results of the study at the 48th Annual Meeting of the American Society of Hematology in Orlando, Florida.

About the Study
ALDESORT enriches a unique population of stem and progenitor cells from cord blood that contribute to neutrophil and platelet engraftment and to immune reconstitution following transplantation. The primary goal of the clinical study is to determine if transplanting these enriched cells is safe. The study will also indicate if transplanting these cell populations could result in accelerated engraftment and lead to more favorable clinical outcomes compared to a historical control group from the Cord Blood Transplantation Trial (COBLT) study, a multicenter Phase II study sponsored by the National Heart, Lung and Blood Institute. At the time of the interim analysis, eleven pediatric patients with cancer or genetic diseases were transplanted with unrelated donor umbilical cord blood and a supplement of cord cells isolated using ALDESORT. Overall survival at 180 days was 90.9%, compared to an overall survival at 180 days of 57% in COBLT study. The cumulative incidence of neutrophil engraftment by day 42 was 90.9% (p=0.001) and platelet engraftment by day 100 was 79.5% (p=0.003).

The findings of this study once again show the promise of transplanting stem cells from umbilical cord blood to treat children with resistant cancers and genetic diseases, said Dr. Kurtzberg. The infusion of cells enriched with ALDESORT has had no adverse effects and appears to improve the speed and efficacy of cord bloo
'"/>

Contact: Michelle Linn
linnmich@comcast.net
508-419-1555
Linnden Communications
11-Dec-2006


Page: 1 2

Related medicine news :

1. Clinical data suggest potential versatility of ALIMTA-based regimens in lung cancer
2. Susan G. Komen for the Cure and American Society of Clinical Oncology partner in national initiative
3. Clinical review -- A psychological approach to the management of irritable bowel syndrome
4. NHLBI Asthma Clinical Research Networks and ALA ACRC Network to present at ATS 2007
5. Clinical trial data for Perforomist Inhalation Solution presented at International ATS Conference
6. Clinical guidelines for blood conservation during cardiac procedures developed
7. Clinical trial data for Perforomist Inhalation Solution to be presented at ATS on May 20, 2007
8. Clinical trial coordinators need more financial conflict-of-interest training
9. Clinical studies evaluate potential treatments for mouth ulcers
10. NIH names Clinical Trial Units for the Microbicide Trials Network
11. Clinical Trials Units selected for newly restructured HIV/AIDS research networks

Post Your Comments:
(Date:7/23/2014)... HealthDay Reporter , TUESDAY, July 22, 2014 ... with double the risk of heart attack or stroke in ... among those whose diabetes isn,t well-managed, a new Japanese study ... consumed an average of 5.9 grams of sodium daily had ... consumed, on average, 2.8 grams of sodium daily. In addition, ...
(Date:7/23/2014)... Tenn. July 22, 2014) The voice on the recording was ... brought the news he was infected with the human immunodeficiency virus ... bit and next thing you know I was on the floor ... the message was hopeful when the recording ended less than 10 ... . . . because it is just God setting you ...
(Date:7/23/2014)... 2014 Follow us on ... exclusively developed and manufactured for use in synthetic ... tissues. These materials are biosafe with significantly lower ... market for biocompatible materials is expected to witness ... advancements and growing base of aging population and ...
(Date:7/23/2014)... OH (PRWEB) July 23, 2014 ... AromaMist™ , SpaRoom’s top product and premier diffuser, is ... rubberized feel and an improved motor for maximum quality. ... all-in-one is now available on SpaRoom.com for $60 along ... smart, safe, ultrasonic pulsations to create a long-lasting, tranquil ...
(Date:7/23/2014)... Follow us on LinkedIn ... the marketing mix, with its benefits ranging from ... purchase decision. In a competitive market environment, packaging ... provides ample opportunities for sales growth. Manufacturers are ... such as blister and other high visibility packaging. ...
Breaking Medicine News(10 mins):Health News:High-Salt Diets Could Double Risk of Heart Woes for Diabetics 2Health News:High-Salt Diets Could Double Risk of Heart Woes for Diabetics 3Health News:HIV clinic-based audio project emphasizes the power of patient voices 2Health News:Surge in R&D Investments to Drive the Global Biocompatible Materials Market, According to New Report by Global Industry Analysts, Inc. 2Health News:Surge in R&D Investments to Drive the Global Biocompatible Materials Market, According to New Report by Global Industry Analysts, Inc. 3Health News:SpaRoom® Unveils New Sleek Color, Improved AromaMist™ 2Health News:Increasing Focus on Packaging as a Marketing Tool Drives the Blister & Other High Visibility Packaging Market, According to New Report by Global Industry Analysts, Inc. 2Health News:Increasing Focus on Packaging as a Marketing Tool Drives the Blister & Other High Visibility Packaging Market, According to New Report by Global Industry Analysts, Inc. 3Health News:Increasing Focus on Packaging as a Marketing Tool Drives the Blister & Other High Visibility Packaging Market, According to New Report by Global Industry Analysts, Inc. 4
(Date:7/23/2014)...  MiMedx Group, Inc.  (NASDAQ: MDXG ... patent-protected regenerative biomaterials and bioimplants processed from human ... initial Investigational New Drug ("IND") application with the ... The IND submission, which was filed yesterday, July ... certain indications of its micronized allografts towards targeted ...
(Date:7/23/2014)... SUNNYVALE, Calif. , July 23, 2014 ... 2014 AUGS/IUGA Scientific Meeting in Washington, D.C. ... a pivotal study of the Pelvalon,s Vaginal Bowel Control ... Director of the Division of Urogynecology and Pelvic Reconstructive ... immediate Past President of the Society for Gynecological Surgeons ...
(Date:7/23/2014)... Indien, July 23, 2014 ... für Arbeiten für Sadara Chemical Company (Sadara) ... Information System innerhalb des integrierten Chemiekomplexes von ... of additional scope im Wert von mehreren ... abgeschlossenen Vertrags dar, dessen Wert sich ebenfalls ...
Breaking Medicine Technology:MiMedx Files Its Initial Investigational New Drug Application 2MiMedx Files Its Initial Investigational New Drug Application 3Pelvalon Announces Results from the LIFE Pivotal Trial at the 2014 AUGS/IUGA Conference 2Rolta gewinnt Follow-on Award für Engineering Systems für Sadara, Saudi-Arabien im Wert von mehreren Millionen Dollar 2Rolta gewinnt Follow-on Award für Engineering Systems für Sadara, Saudi-Arabien im Wert von mehreren Millionen Dollar 3Rolta gewinnt Follow-on Award für Engineering Systems für Sadara, Saudi-Arabien im Wert von mehreren Millionen Dollar 4
Cached News: